| Citation: |
GU Li'na, SANG Meixiang, LIU Fei, WU Yunyan, LIU Shina, HUANG Weina, WANG Pengyu, LIAN Yishui, SHAN Baoen. Expressions of Melanoma Antigen-As in Lung Adenocarcinoma Tissues and Related Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2017, 44(8): 530-534. DOI: 10.3971/j.issn.1000-8578.2017.16.1316
|
To investigate the expression of melanoma antigen (MAGE) -As in lung adenocarcinoma(LAC) tissues, and to explore their correlation with clinical biological indicators and prognostic factors.
We collected cancerous and adjacent lung cancer tissue specimens from 80 patients with lung cancer who were surgically treated in the Fourth Hospital of Hebei Medical University. Testicular tissues (n=5) were collected from the patients with prostate cancer as positive control in the same time. Immunohistochemical staining was performed to assess the expression of MAGE-As in carcinoma and adjacent tissues.
MAGE-As protein were not expressed in adjacent tissues, the positive expression rate of MAGE-As protein in LAC tissues was 46.25%(37/80). No correlation was found between MAGE-As protein expression and age, gender, histological grade, clinical stage, tumor size, lymph node metastasis in LAC patients (P > 0.05). Log rank test showed that the survival time of LAC patients with positive MAGE-As expression was lower than that of negative ones (P=0.007). Multivariate analysis results showed that MAGE-As expression, age and clinical stage were independent risk factors of LAC.
MAGE-As proteins are LAC-associated antigens, thus, they have potentially diagnostic and prognostic significance in clinical settings.
| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Ciln, 2015, 65(1): 5-29. doi: 10.3322/caac.21254
|
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-32. doi: 10.3322/caac.21338
|
| [3] |
Salmaninejad A, Zamani MR, Pourvahedi M, et al. Cancer/Testis antigens: expression, regulation, tumor invasion and use in immunotherapy of cancers[J]. Immuol Invest, 2016, 45(7): 619-40. doi: 10.1080/08820139.2016.1197241
|
| [4] |
Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma[J]. Science, 1991, 254 (5038): 1643-7. doi: 10.1126/science.1840703
|
| [5] |
Wang D, Wang J, Ding N, et al. MAGE-A1 promotes melanoma proliferation and migration through C-JUN activation[J]. Biochem Biophys Res Commun, 2016, 473(4): 959-65. doi: 10.1016/j.bbrc.2016.03.161
|
| [6] |
Hou SY, Sang MX, Geng CZ, et al. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism[J]. Arch Med Res, 2014, 45(1): 44-51. doi: 10.1016/j.arcmed.2013.10.005
|
| [7] |
Liu SH, Sang M, Xu Y, et al. Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study[J]. Acta Otolaryngol, 2016, 136(5): 506-13. doi: 10.3109/00016489.2015.1126856
|
| [8] |
Mengus C, Schultz-Thater E, Coulot J, et al. MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas[J]. Int J Cancer, 2013, 132(10): 2459-63. doi: 10.1002/ijc.27914
|
| [9] |
谷丽娜, 桑梅香, 刘飞, 等.黑素瘤相关抗原-A9和-A11在食管鳞状细胞癌组织中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2015, 22(5): 630-6. doi: 10.3872/j.issn.1007-385X.2015.05.014
Gu LN, Sang MX, Liu F, et al. expression and clinical significance of melanoma antigen-a9 and a11 in esophageal squamous cell caricinoma tissues[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2015, 22(5): 630-6. doi: 10.3872/j.issn.1007-385X.2015.05.014
|
| [10] |
Guo L, Sang M, Liu Q, et al. The expression and clinical significance of melanoma-associated antigen-A1, -A3 and -A11 in glioma[J]. Oncol Lett, 2013, 6(1): 55-62.
|
| [11] |
刘维华, 桑梅香, 单保恩.黑色素瘤相关抗原-A:食管癌免疫治疗新靶点[J].肿瘤防治研究, 2015, 42(6): 622-6. http://www.zlfzyj.com/CN/abstract/abstract8525.shtml
Liu WH, Sang MX, Shan BE. MAGE-A: New Target of Immunotherapy for Esophageal Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(6): 622-6. http://www.zlfzyj.com/CN/abstract/abstract8525.shtml
|
| [12] |
Brahmer JR. Harnessing the immune system for the treatment of non-small-cell-lung cancer[J]. J Clin Oncol, 2013, 31(8): 1021-8. doi: 10.1200/JCO.2012.45.8703
|
| [13] |
Pujol JL, Vansteenkiste JF, De Pas TM, et al. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage ⅠB to Ⅲ MAGE-A3-Positive Non-Small-Cell Lung Cancer[J]. J Thorac Oncol, 2015, 10(10): 1458-67. doi: 10.1097/JTO.0000000000000653
|
| [14] |
Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phaseⅡ randomized study results[J]. J Clin Oncol, 2013, 31(1): 2396-403. doi: 10.1200/JCO.2012.43.7103
|
| [15] |
Karimi S, Mohammadi F, Porabdollah M, et al. Characterization of melanoma-associated antigen-a genes family differential expression in non-small-cell lung cancers[J]. Clin Lung Cancer, 2012, 13(3): 214-9. doi: 10.1016/j.cllc.2011.09.007
|
| [16] |
Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(6): 822-35. doi: 10.1016/S1470-2045(16)00099-1
|
| [17] |
Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in Stages Ⅰ and Ⅱ non-small cell lung cancer: results of a multi-center study[J]. Eur J Cardiothorac Surg, 2004, 25 (1): 131-4. doi: 10.1016/j.ejcts.2003.09.015
|
| [18] |
Peikert T, Specks U, Farver C, et al. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis[J]. Cancer Res, 2006, 66(9): 4693-700. doi: 10.1158/0008-5472.CAN-05-3327
|
| [19] |
Karimi S, Mohammadi F, Porabdollah M, et al. Characterization of melanoma-associated antigen-a genes family differential expression in non-small-cell lung cancers[J]. Clin Lung Cancer, 2012, 13(3): 214-9. doi: 10.1016/j.cllc.2011.09.007
|
| [20] |
Zhang S, Zhai X, Wang G, et al. High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival[J]. Int J Clin Exp Pathol, 2015, 8(1): 541-50. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348844/
|
| [21] |
Zhai X, Xu L, Zhang S, et al. High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma[J]. Oncotarget, 2016, 7(4): 4871-81. doi: 10.18632/oncotarget.v7i4
|
| [22] |
Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class Ⅰ major histocompatibility complex-encoded molecules[J]. Cancer Immunol Immunother, 2009, 58(4): 589-601. doi: 10.1007/s00262-008-0582-6
|
| [23] |
Liu XL, Sun N, Dong YN, et al. Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells[J]. Int Immunopharmacol, 2015, 25(2): 416-24. doi: 10.1016/j.intimp.2015.02.017
|
| [24] |
Jin J, Liu BZ, Wu ZM. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer treatment[J]. J Cancer Res Ther, 2015, 11(8): 271-4. doi: 10.4103/0973-1482.170549
|
| [1] | XIE Yuhua, LI Shengjin. Disease Spectrum and Prognosis of Rare Lung Malignancies[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 432-436. DOI: 10.3971/j.issn.1000-8578.2020.19.1169 |
| [2] | CHEN Ni'na, ZHAO Lei, CAO Bangwei. Cholesterol: A Predictor of Risk and Prognosis of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(9): 847-850. DOI: 10.3971/j.issn.1000-8578.2019.19.0265 |
| [3] | DONG Fei, PANG Meng, ZHENG Dong, ZHEN Jingfei, JING Hongmei. Clinical Characteristics and Prognosis of Primary Thyroid Lymphoma Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(6): 515-518. DOI: 10.3971/j.issn.1000-8578.2019.18.1561 |
| [4] | ZHANG Wenlong, ZHANG Panpan, SI Jiahui, MA Yuanyuan, YANG Yue. HLA-G Expression in Lung Adenocarcinoma Tissues and Its Relationship with Prognosis[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 566-570. DOI: 10.3971/j.issn.1000-8578.2018.17.1594 |
| [5] | LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007 |
| [6] | GUO Jiajia, PENG Yuan, WANG Shu. Prognosis-related Factors of Bilateral Primary Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 150-153. DOI: 10.3971/j.issn.1000-8578.2015.02.011 |
| [7] | LU Xianzhou, LIU Longfei, ZHOU Xiaojun, XIAO Shuai, LONG Jianwu, ZHOU Xian. GPR124 Expression and Its Relationship with Prognosis in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(10): 1082-1086. DOI: 10.3971/j.issn.1000-8578.2014.10.006 |
| [8] | HE Lang, HOU Mei, LI Chang-lin, LI Guang-ming. Unsuitable Marker for PKCα to Predict Prognosis of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(01): 66-69. DOI: 10.3971/j.issn.1000-8578.2010.01.018 |
| [9] | TIAN Feng, WANG Tian-you, CHANG Dong, GONG Min, TONG Yu-jun. Expression of COX-2 and survivin in Esophageal Carcinoma and Relationship with Prognosis[J]. Cancer Research on Prevention and Treatment, 2009, 36(03): 203-206. DOI: 10.3971/j.issn.1000-8578.2009.03.010 |
| [10] | GE Pei-lin, ZHONG Yun-ping. Prognosis Analysis of Low Grade Gliomas[J]. Cancer Research on Prevention and Treatment, 2005, 32(07): 438-439. DOI: 10.3971/j.issn.1000-8578.1262 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: